Literature DB >> 2373830

Low energy synchronous transcatheter cardioversion of atrial flutter/fibrillation in the dog.

K Kumagai1, Y Yamanouchi, N Tashiro, T Hiroki, K Arakawa.   

Abstract

The feasibility and effectiveness of low energy synchronous transcatheter cardioversion of atrial flutter and fibrillation were examined in dogs with talc-induced pericarditis. A conventional electrode catheter was positioned transvenously in the right atrial appendage. Atrial flutter/fibrillation was induced by using the train pulse method, and the tachyarrhythmia-inducing threshold was determined. The minimal effective cardioversion energy levels were compared in three different cardioversion methods: method A = delivery of shock between the proximal electrode (cathode) and the backplate (anode), method B = delivery between the proximal electrode (cathode) and the distal electrode (anode) and method C = conventional external cardioversion. In both methods A and B, all 149 cardioversion attempts were successful with shocks of less than or equal to 5 J. Shocks of less than or equal to 1 J resulted in successful cardioversion in 57 (70%) of 81 attempts, 50 (74%) of 68 attempts and 5 (12%) of 41 attempts with methods A, B and C, respectively. The mean minimal effective cardioversion energy levels were not significantly different between methods A and B (0.62 +/- 0.67 versus 0.58 +/- 0.71 J). Transcatheter cardioversion decreased the defibrillation threshold 3- to 75-fold (mean 6- to 7-fold) from that of transthoracic cardioversion. The defibrillation threshold was not influenced by the inducibility of atrial flutter/fibrillation. There were no complications of heart block, ventricular fibrillation or pathologic evidence of severe shock-induced atrial injury. Thus, low energy synchronous transcatheter cardioversion of atrial flutter/fibrillation is considered feasible and effective. This technique may also be useful in managing the atrial flutter/fibrillation that can occur during electrophysiologic studies.

Entities:  

Mesh:

Year:  1990        PMID: 2373830     DOI: 10.1016/0735-1097(90)90610-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

Review 1.  New devices and hybrid therapies and new devices for treatment of atrial fibrillation.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

2.  Pharmacologic enhancement of atrial electrical defibrillation efficacy: role of ibutilide.

Authors:  D S Khoury; M D Assar; H Sun
Journal:  J Interv Card Electrophysiol       Date:  1997-12       Impact factor: 1.900

3.  Low energy internal cardioversion of atrial fibrillation resistant to transthoracic shocks.

Authors:  S M Sopher; F D Murgatroyd; A K Slade; I Blankoff; E Rowland; D E Ward; A J Camm
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 4.  Low-energy internal cardioversion of atrial fibrillation after failed external cardioversion: Texas Heart Institute experience and review of the literature.

Authors:  M Zaqqa; H Afshar; G R Khoshnevis; J A Lopez; A Massumi
Journal:  Tex Heart Inst J       Date:  1999

Review 5.  Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

6.  Efficacy of a new balloon catheter for internal cardioversion of chronic atrial fibrillation without anaesthesia.

Authors:  E Alt; R Ammer; G Lehmann; C Schmitt; J Pasquantonio; A Schömig
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

Review 7.  Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology.

Authors:  Dobromir Dobrev; Stanley Nattel; Jordi Heijman; Roddy Hiram; Na Li
Journal:  Nat Rev Cardiol       Date:  2022-09-15       Impact factor: 49.421

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.